Review Article| Volume 43, ISSUE 4, P791-810, December 2022

Management of Mental Health in Cystic Fibrosis


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Chest Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Quittner A.L.
        • Goldbeck L.
        • Abbott J.
        • et al.
        Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the International Depression Epidemiological Study across nine countries.
        Thorax. 2014; 69: 1090-1097
        • Schechter M.S.
        • Ostrenga J.S.
        • Fink A.K.
        • et al.
        Decreased survival in cystic fibrosis patients with a positive screen for depression.
        J Cyst Fibros. 2021; 20: 120-126
        • Smith B.A.
        • Georgiopoulos A.M.
        • Quittner A.L.
        Maintaining mental health and function for the long run in cystic fibrosis.
        Pediatr Pulmonol. 2016; 51: S71-S78
      1. Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report Bethesda, Maryland ©2021, Cystic Fibrosis Foundation.

        • Muther E.F.
        • Polineni D.
        • Sawicki G.S.
        Overcoming psychosocial challenges in cystic fibrosis: promoting resilience.
        Pediatr Pulmonol. 2018; 53: S86-S92
        • Dagenais R.V.E.
        • Su V.C.H.
        • Quon B.S.
        Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review.
        J Clin Med. 2021; 10: 23
        • McKinzie C.J.
        • Goralski J.L.
        • Noah T.L.
        • et al.
        Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis.
        J Cyst Fibros. 2017; 16: 525-527
        • Talwalkar J.S.
        • Koff J.L.
        • Lee H.B.
        • et al.
        Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis.
        Psychosomatics. 2017; 58: 343-354
        • Tindell W.
        • Su A.
        • Oros S.M.
        • et al.
        Trikafta and psychopathology in cystic fibrosis: a case report.
        Psychosomatics. 2020; 61: 735-738
        • Bathgate C.J.
        • Barboa C.
        Mental health and neurocognitive side effects after initiating elexacaftor/tezacaftor/ivacaftor.
        J Cyst Fibros. 2021; 20S2: S130
        • Heo S.
        • Young D.C.
        • Safirstein J.
        • et al.
        Mental status changes during elexacaftor/tezacaftor/ivacaftor therapy.
        J Cyst Fibros. 2021; 21: 339-343
        • Martin C.
        • Burnet E.
        • Ronayette-Preira A.
        • et al.
        Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
        Respir Med Res. 2021; 80: 100829
        • Prieur M.G.
        • Christon L.M.
        • Mueller A.
        • et al.
        Promoting emotional wellness in children with cystic fibrosis, Part I: child and family resilience.
        Pediatr Pulmonol. 2021; 56: S97-S106
        • American Psychiatric Association
        Diagnostic and statistical manual of mental disorders.
        5th edition. Author, Washington, DC2013
        • Kroenke K.
        • Spitzer R.L.
        • Williams J.B.
        The PHQ-9: validity of a brief depression severity measure.
        J Gen Intern Med. 2001; 16: 606-613
        • Spitzer R.L.
        • Kroenke K.
        • Williams J.B.
        • et al.
        A brief measure for assessing generalized anxiety disorder: the GAD-7.
        Arch Intern Med. 2006; 166: 1092-1097
        • Quittner A.L.
        • Abbott J.
        • Georgiopoulos A.M.
        • et al.
        International Committee on mental health in cystic fibrosis: cystic fibrosis Foundation and European cystic fibrosis Society consensus statements for screening and treating depression and anxiety.
        Thorax. 2015; 71: 26-34
        • Quittner A.L.
        • Abbott J.
        • Hussain S.
        • et al.
        Integration of mental health screening and treatment into cystic fibrosis clinics: evaluation of initial implementation in 84 programs across the United States.
        Pediatr Pulmonol. 2020; 55: 2995-3004
        • Abbott J.
        • Havermans T.
        • Jarvholm S.
        • et al.
        Mental Health screening in cystic fibrosis centres across Europe.
        J Cyst Fibros. 2019; 18: 299-303
        • Smith B.A.
        • Georgiopoulos A.M.
        • Mueller A.
        • et al.
        Impact of COVID-19 on mental health: effects on screening, care delivery, and people with cystic fibrosis.
        J Cyst Fibros. 2021; 20: 31-38
        • Georgiopoulos A.M.
        • Christon L.M.
        • Filigno S.S.
        • et al.
        Promoting emotional wellness in children with CF, part II: mental health assessment and intervention.
        Pediatr Pulmonol. 2021; 56: S107-S122
        • Sheldrick R.C.
        • Henson B.S.
        • Merchant S.
        • et al.
        The Preschool Pediatric Symptom Checklist (PPSC): development and initial validation of a new social/emotional screening instrument.
        Acad Pediatr. 2012; 12: 456-467
        • Jellinek M.S.
        • Murphy J.M.
        • Robinson J.
        • et al.
        Pediatric Symptom Checklist: screening school-age children for psychosocial dysfunction.
        J Pediatr. 1988; 112: 201-209
        • Murphy J.M.
        • Bergmann P.
        • Chiang C.
        • et al.
        The PSC-17: Subscale Scores, reliability, and factor structure in a new national sample.
        Pediatrics. 2016; 138: e20160038
        • Ayers S.
        • Muller I.
        • Mahoney L.
        • et al.
        Understanding needle-related distress in children with cystic fibrosis.
        Br J Health Psychol. 2011; 16: 329-343
        • Cherkasova M.V.
        • Roy A.
        • Molina B.S.G.
        • et al.
        Review: adult outcome as seen through controlled prospective Follow-up studies of children with attention-deficit/hyperactivity disorder followed into adulthood.
        J Am Acad Child Adolesc Psychiatry. 2021; 61: 378-391
        • Freeman D.
        • Sheaves B.
        • Waite F.
        • et al.
        Sleep disturbance and psychiatric disorders.
        Lancet Psychiatry. 2020; 7: 628-637
        • American Academy of Sleep Medicine
        International classification of sleep disorders.
        3rd edition. Author, Darien, IL2014
        • Shakkottai A.
        • O'Brien L.M.
        • Nasr S.Z.
        • et al.
        Sleep disturbances and their impact in pediatric cystic fibrosis.
        Sleep Med Rev. 2018; 42: 100-110
        • Perin C.
        • Fagondes S.C.
        • Casarotto F.C.
        • et al.
        Sleep findings and predictors of sleep desaturation in adult cystic fibrosis patients.
        Sleep Breath. 2012; 16: 1041-1048
        • Godart N.T.
        • Perdereau F.
        • Rein Z.
        • et al.
        Comorbidity studies of eating disorders and mood disorders. Critical review of the literature.
        J affective Disord. 2007; 97: 37-49
        • Quick V.
        • Byrd-Bredbenner C.
        Disordered eating and body image in cystic fibrosis. Diet and exercise in cystic fibrosis.
        Academic Press, San Diego (CA)2015: 11-18
        • Winston A.P.
        Eating disorders and diabetes.
        Curr Diabetes Rep. 2020; 20: 32
        • Mégarbane B.
        • Chevillard L.
        The large spectrum of pulmonary complications following illicit drug use: features and mechanisms.
        Chem Biol Interact. 2013; 206: 444-451
        • Grant B.F.
        • Stinson F.S.
        • Dawson D.A.
        • et al.
        Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
        Arch Gen Psychiatry. 2004; 61: 807-816
        • Lowery E.M.
        • Afshar M.
        • West N.
        • et al.
        Self-reported alcohol use in the cystic fibrosis community.
        J Cyst Fibros. 2020; 19: 84-90
        • Stephen M.J.
        • Chowdhury J.
        • Tejada L.A.
        • et al.
        Use of medical marijuana in cystic fibrosis patients.
        BMC Complement Med therapies. 2020; 20: 323
        • Drees D.
        • Tumin D.
        • Miller R.
        • et al.
        Chronic opioid use and clinical outcomes in lung transplant recipients: a single-center cohort study.
        Clin Respir J. 2018; 12: 2446-2453
        • Ramsey M.L.
        • Lara L.F.
        • Gariepy C.E.
        • et al.
        National trends of hospitalizations in cystic fibrosis highlight a need for pediatric to adult transition clinics.
        Pancreas. 2021; 50: 704-709
        • Castellani C.
        • Duff A.J.A.
        • Bell S.C.
        • et al.
        ECFS best practice guidelines: the 2018 revision.
        J Cyst Fibros. 2018; 17: 153-178
        • Bell S.C.
        • Robinson P.J.
        Cystic fibrosis standards of care, Australia.
        North Ryde, Sydney, NSW2008
        • Friedman D.
        • Quittner A.L.
        • Smith B.
        • et al.
        Preventing depression and anxiety: results of a pilot study of a CF-specific CBT intervention for adults with CF.
        Pediatr Pulmonol. 2019; 54: 397
        • Graziano S.
        • Boldrini F.
        • Righelli D.
        • et al.
        Psychological interventions during COVID pandemic: telehealth for individuals with cystic fibrosis and caregivers.
        Pediatr Pulmonol. 2021; 56: 1976-1984
        • Bathgate C.J.
        • Kilbourn K.M.
        • Murphy N.H.
        • et al.
        Pilot RCT of a telehealth intervention to reduce symptoms of depression and anxiety in adults with cystic fibrosis.
        J Cyst Fibros. 2022; 21: 332-338
        • O'Hayer C.V.
        • O'Loughlin C.M.
        • Nurse C.N.
        • et al.
        ACT with CF: a telehealth and in-person feasibility study to address anxiety and depressive symptoms among people with cystic fibrosis.
        J Cyst Fibros. 2021; 20: 133-139
        • Thabrew H.
        • Stasiak K.
        • Hetrick S.E.
        • et al.
        Psychological therapies for anxiety and depression in children and adolescents with long-term physical conditions.
        Cochrane Database Syst Rev. 2018; 12: Cd012488
        • Jane Garland E.
        • Kutcher S.
        • Virani A.
        • et al.
        Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice.
        J Can Acad Child Adolesc Psychiatry. 2016; 25: 4-10
      2. Georgiopoulos A, Friedman D, Sher Y. Best practice guide: Management of depression and anxiety Improving Life with CF: A Primary Palliative Care Partnership 2021.
        (Available at:) (Accessed October 28, 2021)
        • Jordan C.L.
        • Noah T.L.
        • Henry M.M.
        Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis.
        Pediatr Pulmonol. 2016; 51: S61-S70
      3. Vertex Pharmaceuticals. Trikafta prescribing information. 2019. Accessed February 6, 2022.

        • McGarry M.E.
        • Williams 2nd, W.A.
        • McColley S.A.
        The demographics of adverse outcomes in cystic fibrosis.
        Pediatr Pulmonol. 2019; 54 Suppl 3: S74-S83
        • Felitti V.J.
        • Anda R.F.
        • Nordenberg D.
        • et al.
        Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study.
        Am J Prev Med. 1998; 14: 245-258
        • Eull D.
        • Postier A.
        • Hermes D.
        • et al.
        Children's Comfort Promise; successfully implementing an evidence based pain protocol for needle procedures throughout a large children's hospital and clinic system.
        J Pain. 2016; 17: S43
        • Kazdin A.E.
        Parent management training and problem-solving skills training for child and adolescent conduct problems.
        in: Weisz J.R. Kazdin A.E. Evidence-based psychotherapies for children and adolescents. 3rd edition. Guilford Press, New York2017: 142-158
        • National Center on Birth Defects and Developmental Disabilities
        Treatment and intervention services for autism Spectrum disorder.
        2019 (Available at:) (Accessed October 28, 2021)
        • Okajima I.
        • Komada Y.
        • Inoue Y.
        A meta-analysis on the treatment effectiveness of cognitive behavioral therapy for primary insomnia.
        Sleep Biol Rhythms. 2011; 9: 24-34
        • Gehrman P.
        • Gunter P.
        • Findley J.
        • et al.
        Randomized noninferiority trial of telehealth delivery of cognitive behavioral treatment of insomnia compared to in-person care.
        J Clin Psychiatry. 2021; 82: 20m13723
        • Taylor D.J.
        • Pruiksma K.E.
        Cognitive and behavioural therapy for insomnia (CBT-I) in psychiatric populations: a systematic review.
        Int Rev Psychiatry (Abingdon, England). 2014; 26: 205-213
        • Chung W.S.
        • Lai C.Y.
        • Lin C.L.
        • et al.
        Adverse respiratory events associated with hypnotics use in patients of chronic obstructive pulmonary disease: a population-based case-control study.
        Medicine. 2015; 94: e1110
        • Klein D.A.
        • Sylvester J.E.
        • Schvey N.A.
        Eating disorders in primary care: diagnosis and management.
        Am Fam Physician. 2021; 103: 22-32
        • Drake R.E.
        • O'Neal E.L.
        • Wallach M.A.
        A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders.
        J Subst Abuse Treat. 2008; 34: 123-138
        • National Institute on Drug Abuse
        Effective treatments for opioid addiction.
        (Available at:) (Accessed October 28, 2021)